Atara Biotherapeutics Appoints Interim CFO/PAO Following Chief Accounting Officer Departure
Summary
Atara Biotherapeutics is changing its financial leadership, with the Chief Accounting Officer departing and an experienced consultant stepping in as interim CFO and Principal Accounting Officer.
Key Events
-
Chief Accounting Officer Departs
Yanina Grant-Huerta, the Company's Chief Accounting Officer, will end her employment effective July 17, 2026.
-
Interim CFO/PAO Appointed
Kevin G. Sarney, Life Science Practice Leader at Charles River CFO, Inc., was appointed interim Chief Financial Officer and Principal Accounting Officer, effective June 26, 2026.
-
Experienced Interim Leader
Mr. Sarney brings over 25 years of finance and accounting experience with life science companies and is a licensed Certified Public Accountant.
Analysis
Atara Biotherapeutics, a company facing a Nasdaq delisting notice and a going concern warning, announced a change in its financial leadership. The Chief Accounting Officer's employment will end, and an experienced consultant from Charles River CFO, Inc. has been appointed as interim Chief Financial Officer and Principal Accounting Officer. While the interim appointment ensures continuity, the change in key financial personnel during a critical period warrants investor attention.
At the time of this filing, ATRA was trading at $10.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.7M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.